Clinical Trial

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-03-23; most recent amendment 2024-10-03.
Status change: Not Yet Recruiting → Recruiting 2022-08-04
Trial Details
NCT Number NCT05305911
Lead Sponsor Minneapolis Heart Institute Foundation
Conditions Heart Attack, Enlarged Heart
Enrollment 81 participants
Start Date 2022-08-03
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2024-10-08